Article Information
vol. 9 no. 2
Published By
Online ISSN
History
- Received August 18, 2022
- Accepted October 20, 2022
- Published online March 6, 2023.
Article Versions
- previous version (November 17, 2022 - 07:12).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright ©The authors 2023 This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Author Information
- Lucia De Prado Gomez1⇑,
- Ian Pavord2,
- William Busse3,
- Christopher E. Brightling4,
- Michael E. Wechsler5,
- Klaus F. Rabe6,7,
- Mei Zhang8,
- Jun Xing8,
- Juby A. Jacob-Nara8 and
- Paul J. Rowe8
- 1Sanofi, Reading, UK
- 2NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
- 3UW Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
- 4Institute for Lung Health, NIHR Leicester Biomedical Research Center, Department of Respiratory Sciences, University of Leicester, Leicester, UK
- 5National Jewish Health, Denver, CO, USA
- 6LungenClinic Grosshansdorf (member of the German Center for Lung Research (DZL)), Airway Research Center North (ARCN), Grosshansdorf, Germany
- 7Christian-Albrechts University (member of the DZL), ARCN, Kiel, Germany
- 8Sanofi, Bridgewater, NJ, USA
- Corresponding author: Lucia De Prado Gomez (Lucia.DePradoGomez{at}sanofi.com)
Funding
Sanofi and Regeneron Pharmaceuticals, Inc.
Article usage
Altmetrics
Vol 9 Issue 2
Table of Contents
Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design
